Notice: This company has been marked as potentially delisted and may not be actively trading. RXi Pharmaceuticals (RXII) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrends RXII vs. HILS, FBIO, GANX, VYNE, AFMD, RVPH, RLYB, XLO, BRNS, and FGENShould you be buying RXi Pharmaceuticals stock or one of its competitors? The main competitors of RXi Pharmaceuticals include Hillstream BioPharma (HILS), Fortress Biotech (FBIO), Gain Therapeutics (GANX), VYNE Therapeutics (VYNE), Affimed (AFMD), Reviva Pharmaceuticals (RVPH), Rallybio (RLYB), Xilio Therapeutics (XLO), Barinthus Biotherapeutics (BRNS), and FibroGen (FGEN). These companies are all part of the "medical" sector. RXi Pharmaceuticals vs. Hillstream BioPharma Fortress Biotech Gain Therapeutics VYNE Therapeutics Affimed Reviva Pharmaceuticals Rallybio Xilio Therapeutics Barinthus Biotherapeutics FibroGen RXi Pharmaceuticals (NASDAQ:RXII) and Hillstream BioPharma (NASDAQ:HILS) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, community ranking, risk, institutional ownership, valuation, media sentiment, dividends, analyst recommendations and earnings. Which has preferable earnings & valuation, RXII or HILS? Hillstream BioPharma has lower revenue, but higher earnings than RXi Pharmaceuticals. Hillstream BioPharma is trading at a lower price-to-earnings ratio than RXi Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRXi Pharmaceuticals$10K1,108.14-$12.45M-$4.20-0.60Hillstream BioPharmaN/AN/A-$8.47M-$0.72-3.47 Does the media favor RXII or HILS? In the previous week, RXi Pharmaceuticals' average media sentiment score of 0.00 equaled Hillstream BioPharma'saverage media sentiment score. Company Overall Sentiment RXi Pharmaceuticals Neutral Hillstream BioPharma Neutral Which has more volatility and risk, RXII or HILS? RXi Pharmaceuticals has a beta of 2.07, meaning that its share price is 107% more volatile than the S&P 500. Comparatively, Hillstream BioPharma has a beta of 3.08, meaning that its share price is 208% more volatile than the S&P 500. Does the MarketBeat Community favor RXII or HILS? RXi Pharmaceuticals received 191 more outperform votes than Hillstream BioPharma when rated by MarketBeat users. Likewise, 68.09% of users gave RXi Pharmaceuticals an outperform vote while only 50.00% of users gave Hillstream BioPharma an outperform vote. CompanyUnderperformOutperformRXi PharmaceuticalsOutperform Votes19268.09% Underperform Votes9031.91% Hillstream BioPharmaOutperform Votes150.00% Underperform Votes150.00% Do insiders and institutionals believe in RXII or HILS? 9.6% of RXi Pharmaceuticals shares are owned by institutional investors. Comparatively, 13.4% of Hillstream BioPharma shares are owned by institutional investors. 1.0% of RXi Pharmaceuticals shares are owned by company insiders. Comparatively, 30.2% of Hillstream BioPharma shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Is RXII or HILS more profitable? Hillstream BioPharma has a net margin of 0.00% compared to RXi Pharmaceuticals' net margin of -4,990.20%. Hillstream BioPharma's return on equity of -188.44% beat RXi Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets RXi Pharmaceuticals-4,990.20% -412.15% -179.54% Hillstream BioPharma N/A -188.44%-149.61% SummaryHillstream BioPharma beats RXi Pharmaceuticals on 8 of the 12 factors compared between the two stocks. Ad Crypto 101 MediaTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… YES, I WANT THE #1 CRYPTO NOW Get RXi Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for RXII and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RXII vs. The Competition Export to ExcelMetricRXi PharmaceuticalsPharmaceutical Preparations IndustryMedical SectorNASDAQ ExchangeMarket Cap$11.08M$6.57B$5.14B$8.84BDividend YieldN/A8.11%5.05%4.07%P/E Ratio-0.609.56125.0517.04Price / Sales1,108.14364.791,232.2287.12Price / CashN/A52.5939.9936.27Price / Book3.2910.176.956.36Net Income-$12.45M$153.36M$119.41M$226.00M RXi Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RXIIRXi PharmaceuticalsN/A$2.53+6.3%N/A+150.2%$11.08M$10,000.00-0.60N/AHILSHillstream BioPharmaN/A$2.50+2.9%N/A+1,057.1%$44.01MN/A-3.471FBIOFortress Biotech3.0757 of 5 stars$1.58flat$13.67+767.7%-43.9%$43.34M$62.50M-0.52186Analyst ForecastAnalyst RevisionGANXGain Therapeutics2.5269 of 5 stars$1.63-1.8%$7.33+349.9%-39.0%$43.23M$50,000.00-1.4820News CoverageVYNEVYNE Therapeutics2.5605 of 5 stars$2.90+2.8%$6.88+137.1%-28.6%$42.78M$420,000.00-3.3730Analyst ForecastAFMDAffimed3.2815 of 5 stars$2.64-2.9%$16.00+506.1%-42.7%$42.50M$8.95M0.0076Analyst ForecastGap UpRVPHReviva Pharmaceuticals2.0675 of 5 stars$1.24+1.6%$15.50+1,150.0%-71.1%$41.47MN/A-1.125RLYBRallybio2.5483 of 5 stars$0.99-1.0%$9.75+886.2%-59.4%$41.02MN/A-0.6240XLOXilio Therapeutics1.9025 of 5 stars$0.92-2.1%$4.00+334.8%-21.6%$40.44MN/A-0.5573BRNSBarinthus Biotherapeutics1.6594 of 5 stars$0.99+10.0%$5.83+490.3%-69.1%$39.08M$800,000.00-0.60107Analyst ForecastFGENFibroGen2.4731 of 5 stars$0.39+11.5%N/A-33.8%$39.02M$147.75M-0.28486Analyst RevisionGap Down Related Companies and Tools Related Companies HILS Alternatives FBIO Alternatives GANX Alternatives VYNE Alternatives AFMD Alternatives RVPH Alternatives RLYB Alternatives XLO Alternatives BRNS Alternatives FGEN Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:RXII) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding RXi Pharmaceuticals Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share RXi Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
